ANKTIVA Secures FDA Pathway For Papillary Urothelial Carcinoma Treatment; Clinical Milestone Reshapes Patient Options

ImmunityBio, Inc. (IBRX) revealed significant regulatory progress regarding its investigational therapy ANKTIVA (nogapendekin alfa inbakicept), designed to address a particularly challenging subset of bladder cancer patients. The company has reached a critical juncture with FDA discussions, positioning itself to resubmit supplemental approval documentation for papillary urothelial carcinoma cases that have failed standard treatment protocols.

The Clinical Problem: Why Papillary NMIBC Patients Face Limited Options

Papillary urothelial carcinoma arising in non-muscle invasive bladder cancer (NMIBC) patients resistant to BCG therapy represents a serious therapeutic gap. Currently, no targeted immunotherapies are approved specifically for this patient population, leaving physicians and patients with largely one option: radical cystectomy—a surgical procedure that removes the entire bladder and carries substantial risks, including permanent urinary dysfunction and significant quality-of-life impacts.

For BCG-resistant patients with papillary disease, the standard surgical approach remains the default despite its invasiveness. This clinical reality underscores the urgent need for alternatives that can preserve organ function while controlling disease.

How ANKTIVA Works: A Novel Immune-Activation Strategy

ANKTIVA operates through a distinct mechanism, functioning as an IL-15 agonist fusion protein engineered to stimulate the body’s own immune defenses. Specifically, the drug activates natural killer (NK) cells and CD8+ T cells—key components of cellular immunity—to recognize and eliminate cancer cells. This immunotherapy approach offers a fundamentally different strategy compared to conventional chemotherapy or surgery.

The drug has already achieved regulatory approval in the United States for NMIBC carcinoma in situ (CIS) with or without papillary tumors. International recognition followed, with approvals granted in the United Kingdom and Saudi Arabia, plus conditional approval from the European Union, demonstrating early clinical acceptance across multiple healthcare systems.

Clinical Trial Data: Evidence For Long-Term Disease Control

The QUILT-3.032 Phase 2/3 trial enrolled 80 patients with BCG-unresponsive papillary NMIBC and tracked outcomes over three years. The results provide compelling evidence for ANKTIVA’s potential as a bladder-sparing alternative:

• 96% bladder cancer-specific survival at 36 months, indicating effective disease control
• Over 80% bladder preservation at three years, demonstrating that most patients retained functional bladders without undergoing cystectomy
• 92% cystectomy-free survival at one year and 82% at three years, showing sustained freedom from surgical intervention

These figures are particularly significant because they contrast sharply with historical surgical outcomes and reflect a chemo-free immunotherapy approach—offering patients disease control without chemotherapy’s systemic toxicity.

FDA Regulatory Path: From Rejection to Resubmission

The regulatory journey has involved strategic dialogue with the FDA. In May 2025, the agency issued a Refusal to File (RTF) letter for the initial supplemental Biologics License Application (sBLA) seeking approval of ANKTIVA plus BCG for BCG-unresponsive papillary NMIBC. However, this decision was not a permanent barrier.

Following a Type B End-of-Phase meeting with FDA leadership, the agency signaled willingness to move forward, requesting a focused data package to be submitted within 30 days. Importantly, the FDA did not mandate additional clinical trials—meaning the existing QUILT-3.032 data package forms the foundation for the resubmission strategy. ImmunityBio stated its intention to provide the requested information promptly, positioning a formal resubmission within realistic timelines.

Expanding the Treatment Paradigm: Broader Papillary Urothelial Carcinoma Access

This regulatory progress represents a watershed moment for papillary urothelial carcinoma management. If approved, ANKTIVA would provide the first targeted immunotherapy option for BCG-resistant papillary disease—directly addressing the current therapeutic void.

Beyond the immediate papillary indication, ImmunityBio’s first-line BCG-naïve NMIBC program continues advancing, with enrollment exceeding initial projections. Interim analysis from this arm showed positive signals for ANKTIVA plus BCG combinations in newly diagnosed patients, suggesting the drug’s potential extends across multiple NMIBC patient populations.

Market Response and Investment Perspective

The regulatory developments resonated in financial markets. Following the announcement, IBRX stock demonstrated substantial appreciation, reflecting investor recognition of the clinical significance and commercial potential associated with establishing the first targeted therapy for this indication. The stock movement underscored market confidence in the regulatory pathway and clinical data supporting the resubmission strategy.

This advancement represents a transformative moment for patients with papillary urothelial carcinoma who currently face the difficult choice between major surgery and untreated disease progression, potentially reshaping the standard-of-care paradigm for this resistant population.